Entest Group Inc

[ronrooster]

Entest BioMedical Inc. (PINK: ENTB) announced today that it has satisfied $841,531 of Notes Payable as well as $83,000 of accrued expenses through the issuance of the Company's non-voting convertible preferred stock to the creditors. The terms of the settlement are disclosed in a form 8K dated May 30, 2017 filed by the Company with the United States Securities and Exchange Commission and publicly available through the SEC's EDGAR system.

Entest BioMedical Inc.'s Chairman and CEO David Koos noted, "The Company is trying to mitigate shareholder concerns regarding the impediment that the Company's debt burden may pose to our forward progress. I believe this action should strengthen our shareholders' belief in our goal to bring small molecule cancer and autoimmune therapies to animals through our subsidiary, Zander Therapeutics Inc."



More: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=223402#.WS8i9GjyvIU#ixzz4igmfgLMg